Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 51, 2008, Pages 20470-20475

  Barabutis, Nektarios ^a,b   Schally, Andrew V ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidative activity; GHRH; Oxidative stress; ROS

Indexed keywords

ANTIOXIDANT; CASPASE 3; CYCLINE; CYCLOOXYGENASE 2; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE IV; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JMR 132; LIPID; NUCLEAR FACTOR KAPPA B P50; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID OXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIOXIDANTS; CELL LINE, TUMOR; ENZYMES; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; OXIDATION-REDUCTION; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; SERMORELIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58149479262     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811209106     Document Type: Article

References (89)

1. Schally, Varga JL (1999) Antagonistic analogs of growth hormone-releasing hormone: New potential antitumor agents. Trends Endocrinol Metab 10:383-391.
2. Schally AV (2008) New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 40:315-322.
3. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone- releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4:33-43.
4. Barabutis N, Schally AV (2008) Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 98:1790-1796.
5. Havt A, et al. (2005) The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 102:17424-17429.
6. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P (1999) Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96:14894-14898.
7. Kiaris H, Schally AV, Kalofoutis A (2005) Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm 70:1-24.
8. Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566.
9. Barabutis N, et al. (2007) Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 104:5575-5579.
10. Kiaris H, Koutsilieris M, Kalofoutis A, Schally AV (2003) Growth hormone-releasing hormone and extra-pituitary tumorigenesis: Therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opin Investig Drugs 12:1385-1394.
11. Kiaris H (2006) GHRH analogs and cancer. Comb Chem High Throughput Screen 9:161.
12. Siejka A, et al. (2003) GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. Life Sci 72:2473-2479.
13. Jarrett JT (2008) Biochemistry: Radicals by reduction. Nature 452:163-164.
14. Rigas B, Sun Y (2008) Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br J Cancer 98:1157-1160.
15. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120:483-495.
16. Pham CG, et al. (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119:529-542.
17. Benhar M, Engelberg D, Levitzki A (2002) ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3:420-425.
18. Schumacker PT (2006) Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 10:175-176.
19. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI (2008) Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 266:6-11.
20. Panayiotidis M (2008) Reactive oxygen species (ROS) in multistage carcinogenesis. Cancer Lett 266:3-5.
21. Ishikawa K, et al. (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320:661-664.
22. Sakurai T, et al. (2008) Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14:156-165.
23. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008) Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68:1777-1785.
24. Trachootham D, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241-252.
25. Letai AG (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8:121-132.
26. Kastan MB (2007) Wild-type p53: Tumors can't stand it. Cell 128:837-840.
27. Degterev A, Yuan J (2008) Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 9:378-390.
28. Juarez JC, et al. (2008) Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 105:7147-7152.
29. Long DJ 2nd, et al. (2002) Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res 62:3030-3036.
30. Sutton A, et al. (2006) Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res 66:2844-2852.
31. Zhou J, Eleni C, Spyrou G, Brune B (2008) The mitochondrial thioredoxin system regulates nitric oxide-induced HIF-1alpha protein. Free Radic Biol Med 44:91-98.
32. Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47-95.
33. Winterbourn CC (2008) Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4:278-286.
34. Souza JM, Peluffo G, Radi R (2008) Protein tyrosine nitration - Functional alteration or just a biomarker? Free Radic Biol Med 45:357-366.
35. Heijnen HF, et al. (2006) Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. Free Radic Biol Med 40:1903-1913.
36. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329:23-38.
37. Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 44:1787-1794.
38. Gaylinn BD, et al. (1993) Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. Mol Endocrinol 7:77-84.
39. Groot K, et al. (1993) Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone. Int J Pept Protein Res 41:162-168.
40. Gurova KV, et al. (2002) Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 21:153-157.
41. Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003) Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 100:11636-11641.
42. Liu B, Chen Y, St Clair DK (2008) ROS and p53: A versatile partnership. Free Radic Biol Med 44:1529-1535.
43. Bensaad K, Vousden KH (2007) p53: New roles in metabolism. Trends Cell Biol 17:286-291.
44. Sablina AA, et al. (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11:1306-1313.
45. Bensaad K, Vousden KH (2005) Savior and slayer: The two faces of p53. Nat Med 11:1278-1279.
46. Siriwardana G, Bradford A, Coy D, Zeitler P (2006) Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 20:2010-2019.
47. Pombo CM, Zalvide J, Gaylinn BD, Dieguez C (2000) Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology 141:2113-2119.
48. Steinmetz R, Zeng P, King DW, Walvoord E, Pescovitz OH (2001) Peptides derived from pro-growth hormone-releasing hormone activate p38 mitogen-activated protein kinase in GH3 pituitary cells. Endocrine 15:119-127.
49. Zeitler P, Siriwardana G (2000) Stimulation of mitogen-activated protein kinase pathway in rat somatotrophs by growth hormone-releasing hormone. Endocrine 12:257-264.
50. Dolado I, et al. (2007) p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11:191-205.
51. Morris GF, Bischoff JR, Mathews MB (1996) Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci USA 93:895-899.
52. Banks, et al. (2006) L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle 5:1719-1729.
53. D'Autreaux B, Toledano MB (2007) ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8:813-824.
54. Zeitler P, Siriwardana G (2002) Antagonism of endogenous growth hormone-releasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells. Endocrine 18:85-90.
55. Rekasi Z, et al. (2005) Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. Proc Natl Acad Sci USA 102:3435-3440.
56. Kurada P, White K (1998) Ras promotes cell survival in Drosophila by downregulating hid expression. Cell 95:319-329.
57. Le Gall M, et al. (2000) The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell 11:1103-1112.
58. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344-362.
59. Aggarwal BB (2004) Nuclear factor-kappaB: The enemy within. Cancer Cell 6:203-208.
60. Ahmed KM, Li JJ (2008) NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 44:1-13.
61. Fan C, Li Q, Ross D, Engelhardt JF (2003) Tyrosine phosphorylation of I kappa B alpha activates NF kappa B through a redox-regulated and c-Src-dependent mechanism following hypoxia/reoxygenation. J Biol Chem 278:2072-2080.
62. Bar-Shai M, Carmeli E, Ljubuncic P, Reznick AZ (2008) Exercise and immobilization in aging animals: The involvement of oxidative stress and NF-kappaB activation. Free Radic Biol Med 44:202-214.
63. Shao J, et al. (2000) Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19:726-736.
64. Huang, Feng L, Oldham EA, Keating MJ, Plunkett W (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395.
65. Blander G, de Oliveira RM, Conboy CM, Haigis M, Guarente L (2003) Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem 278:38966-38969.
66. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425-437.
67. Gouaze V, et al. (2002) Glutathione peroxidase-1 protects from CD95-induced apoptosis. J Biol Chem 277:42867-42874.
68. Cao C, Leng Y, Huang W, Liu X, Kufe D (2003) Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem 278:39609-39614.
69. Faraonio R, et al. (2006) p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281:39776-39784.
70. Im JY, Kim D, Paik SG, Han PL (2006) Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radic Biol Med 41:960-972.
71. Pratt PF, Bokemeyer D, Foschi M, Sorokin A, Dunn MJ (2003) Alterations in subcellular localization of p38 MAPK potentiates endothelin-stimulated COX-2 expression in glomerular mesangial cells. J Biol Chem 278:51928-51936.
72. Rodriguez C, et al. (2008) COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration. Cell Signal. 20:1625-1631.
73. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M (2000) Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20:2175-2183.
74. Torres M, Forman HJ (2003) Redox signaling and the MAP kinase pathways. Biofactors 17:287-296.
75. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL (2004) Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 22:1141-1149.
76. Suzaki Y, et al. (2002) Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: Potential role in cell survival following oxidative insults. J Biol Chem 277:9614 -9621.
77. Mehdi MZ, Pandey NR, Pandey SK, Srivastava AK (2005) H2O2-induced phosphorylation of ERK1/2 and PKB requires tyrosine kinase activity of insulin receptor and c-Src. Antioxid Redox Signal 7:1014-1020.
78. Marques CA, et al. (2003) Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: Oxidative stress, caspases, and the JNK pathway. J Biol Chem 278:28294-28302.
79. Furst R, et al. (2005) Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ Res 96:43-53.
80. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 87:245-313.
81. Avogaro A, de Kreutzenberg SV, Fadini GP (2008) Oxidative stress and vascular disease in diabetes: Is the dichotomization of insulin signaling still valid? Free Radic Biol Med 44:1209-1215.
82. Asaumi H, Watanabe S, Taguchi M, Tashiro M, Otsuki M (2007) Externally applied pressure activates pancreatic stellate cells through the generation of intracellular reactive oxygen species. Am J Physiol Gastrointest Liver Physiol 293:G972-G978.
83. Bubici C, Papa S, Dean K, Franzoso G (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: Molecular basis and biological significance. Oncogene 25:6731-6748.
84. Finkel T (2005) Radical medicine: Treating ageing to cure disease. Nat Rev Mol Cell Biol 6:971-976.
85. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247.
86. Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948.
87. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622.
88. Przedborski S, Ischiropoulos H (2005) Reactive oxygen and nitrogen species: Weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 7:685-693.
89. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795.